These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, Morris RE. Transplantation; 2000 Feb 27; 69(4):488-96. PubMed ID: 10708100 [Abstract] [Full Text] [Related]
9. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB. Transplantation; 1991 Jan 27; 51(1):107-13. PubMed ID: 1846250 [Abstract] [Full Text] [Related]
10. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, Pilson RS, Lin P, Weber DV, Spence C. J Immunol; 1991 Aug 15; 147(4):1352-9. PubMed ID: 1869828 [Abstract] [Full Text] [Related]
16. The mechanism of synergistic interaction between anti-interleukin 2 receptor monoclonal antibody and cyclosporine therapy in rat recipients of organ allografts. Ueda H, Hancock WW, Cheung YC, Diamantstein T, Tilney NL, Kupiec-Weglinski JW. Transplantation; 1990 Oct 15; 50(4):545-50. PubMed ID: 2219270 [Abstract] [Full Text] [Related]